{"id":40314,"date":"2021-07-28T11:53:38","date_gmt":"2021-07-28T09:53:38","guid":{"rendered":"https:\/\/newserver.fyb.de\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/"},"modified":"2021-07-28T11:53:38","modified_gmt":"2021-07-28T09:53:38","slug":"nrw-venture-growth-financing-for-cevec-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/","title":{"rendered":"NRW.Venture: Growth financing for CEVEC Pharmaceuticals"},"content":{"rendered":"<p>Colo\u00adgne \u2014 NRW.BANK is inves\u00adt\u00ading in CEVEC Phar\u00admaceu\u00adti\u00adcals GmbH via NRW.Venture as part of a growth finan\u00adcing round. The Colo\u00adgne-based company is active in the gene therapy market and is a leading provi\u00adder of tech\u00adno\u00adlo\u00adgies for the produc\u00adtion of biophar\u00admaceu\u00adti\u00adcals. The invest\u00adment is inten\u00added to expand capa\u00adci\u00adties for the growing gene therapy market.<\/p>\n<p>\u201cGene thera\u00adpies have become an important future market in phar\u00admaceu\u00adti\u00adcals and biotech\u00adno\u00adlogy,\u201d says  <strong>Dr. Aris\u00adto\u00adte\u00adlis Nastos, Team Leader Life Scien\u00adces \/ Venture Capi\u00adtal at NRW.BANK<\/strong> and member of the Advi\u00adsory Board of CEVEC Phar\u00admaceu\u00adti\u00adcals GmbH \u201cThe poten\u00adtial for tech\u00adno\u00adlo\u00adgies such as those offe\u00adred by CEVEC is enorm\u00adous and we are plea\u00adsed to be part of this finan\u00adcing round and to support the company\u2019s further growth.\u201d<\/p>\n<p>Gene thera\u00adpies are being deve\u00adlo\u00adped for dise\u00ada\u00adses such as cancer, Alzhei\u00admer\u2019s and Parkin\u00adson\u2019s, among others, leading to a high demand for produc\u00adtion capa\u00adcity. CEVEC offers phar\u00admaceu\u00adti\u00adcal compa\u00adnies modern manu\u00adfac\u00adtu\u00adring solu\u00adti\u00adons here. To address the growing market, the company plans to use the funds from the finan\u00adcing round to expand its capacity.<\/p>\n<p>NRW.BANK has held a stake in CEVEC Phar\u00admaceu\u00adti\u00adcals GmbH since 2009 and has been support\u00ading the company with its network and capi\u00adtal ever since. Through NRW.Venture, it supports start-ups and young compa\u00adnies from North Rhine-West\u00adpha\u00adlia in the deve\u00adlo\u00adp\u00adment and marke\u00adting of inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies and busi\u00adness models and the rapid expan\u00adsion of their business.<\/p>\n<p><strong>About NRW.Venture<\/strong><\/p>\n<p>NRW.Venture is the venture fund of NRW.BANK, the deve\u00adlo\u00adp\u00adment bank for North Rhine-West\u00adpha\u00adlia. It supports its owner, the state of NRW, in its struc\u00adtu\u00adral and econo\u00admic policy tasks. To this end, NRW.BANK uses a wide range of deve\u00adlo\u00adp\u00adment instru\u00adments: from low-inte\u00adrest deve\u00adlo\u00adp\u00adment loans to equity finan\u00adcing and consul\u00adting services. With NRW.Venture, it supports start-ups in the deve\u00adlo\u00adp\u00adment and marke\u00adting of inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies and busi\u00adness models and the rapid expan\u00adsion of their busi\u00adness. NRW.BANK invests <strong>up to ten million euros<\/strong> in such compa\u00adnies over seve\u00adral finan\u00adcing rounds \u2014 toge\u00adther with private-sector inves\u00adtors. www.nrwbank.de\/venture<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Colo\u00adgne \u2014 NRW.BANK is inves\u00adt\u00ading in CEVEC Phar\u00admaceu\u00adti\u00adcals GmbH via NRW.Venture as part of a growth finan\u00adcing round. The Colo\u00ad\u00adgne-based company is active in the gene therapy market and is a leading provi\u00adder of tech\u00adno\u00adlo\u00adgies for the produc\u00adtion of biophar\u00admaceu\u00adti\u00adcals. The invest\u00adment is inten\u00added to expand capa\u00adci\u00adties for the growing gene therapy market. \u201cGene therapies&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37903,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1369,1371,1373],"tags":[],"class_list":["post-40314","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-investors","category-deals-en","category-venture-capital-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NRW.Venture: Growth financing for CEVEC Pharmaceuticals - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NRW.Venture: Growth financing for CEVEC Pharmaceuticals - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Colo\u00adgne \u2014 NRW.BANK is inves\u00adt\u00ading in CEVEC Phar\u00admaceu\u00adti\u00adcals GmbH via NRW.Venture as part of a growth finan\u00adcing round. The Colo\u00adgne-based company is active in the gene therapy market and is a leading provi\u00adder of tech\u00adno\u00adlo\u00adgies for the produc\u00adtion of biophar\u00admaceu\u00adti\u00adcals. The invest\u00adment is inten\u00added to expand capa\u00adci\u00adties for the growing gene therapy market. \u201cGene thera\u00adpies [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-28T09:53:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"NRW.Venture: Growth financing for CEVEC Pharmaceuticals\",\"datePublished\":\"2021-07-28T09:53:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/\"},\"wordCount\":338,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers\/Tax-advisors\/Auditors\",\"Investors\",\"DEALS\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/\",\"url\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/\",\"name\":\"NRW.Venture: Growth financing for CEVEC Pharmaceuticals - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg\",\"datePublished\":\"2021-07-28T09:53:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg\",\"width\":768,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NRW.Venture: Growth financing for CEVEC Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NRW.Venture: Growth financing for CEVEC Pharmaceuticals - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"NRW.Venture: Growth financing for CEVEC Pharmaceuticals - FYB Financial Yearbook","og_description":"Colo\u00adgne \u2014 NRW.BANK is inves\u00adt\u00ading in CEVEC Phar\u00admaceu\u00adti\u00adcals GmbH via NRW.Venture as part of a growth finan\u00adcing round. The Colo\u00adgne-based company is active in the gene therapy market and is a leading provi\u00adder of tech\u00adno\u00adlo\u00adgies for the produc\u00adtion of biophar\u00admaceu\u00adti\u00adcals. The invest\u00adment is inten\u00added to expand capa\u00adci\u00adties for the growing gene therapy market. \u201cGene thera\u00adpies [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2021-07-28T09:53:38+00:00","og_image":[{"width":768,"height":768,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"NRW.Venture: Growth financing for CEVEC Pharmaceuticals","datePublished":"2021-07-28T09:53:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/"},"wordCount":338,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg","articleSection":["General","Featured","News","Lawyers\/Tax-advisors\/Auditors","Investors","DEALS","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/","url":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/","name":"NRW.Venture: Growth financing for CEVEC Pharmaceuticals - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg","datePublished":"2021-07-28T09:53:38+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2021\/07\/dr-aristotelis-nastos-teamleiter-life-sciences-nrw-bank.jpeg","width":768,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/nrw-venture-growth-financing-for-cevec-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NRW.Venture: Growth financing for CEVEC Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/40314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=40314"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/40314\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/37903"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=40314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=40314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=40314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}